Physician profile
Hunter D Smith
NPI 1174180368
$5,352.58
in general payments reported to CMS, 2019-2025
26 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.12 · 2020: $61.33 · 2021: $324 · 2022: $493 · 2023: $2,140 · 2024: $1,780 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Travel and Lodging: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.18 |
| Travel and Lodging | $2,190.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,741.21 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neuropace, INC. | $1,709.85 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $294.36 | 2022-2024 | |
| Ucb, INC. | $267.12 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Sk Life Science, INC. | $183.48 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $173.49 | 2021-2025 | Ultomiris |
| Medtronic, INC. | $135.75 | 2023 | |
| Greenwich Biosciences, INC. | $118.23 | 2019-2021 | |
| Amgen INC. | $109.03 | 2022-2025 | Uplizna |
| Biomarin Pharmaceutical INC. | $89.39 | 2023 | Brineura |
| Abbvie INC. | $71.32 | 2025 | |
| Pfizer INC. | $51.72 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.81 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $44.39 | 2024 | |
| Allergan, INC. | $40.84 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $40.01 | 2022 | |
| Tg Therapeutics, INC. | $32.93 | 2025 | |
| Cycle Pharmaceuticals INC | $29.24 | 2025 | Tascenso Odt, Bafiertam |
| Biogen, INC. | $25.57 | 2025 | Vumerity |
| Sumitomo Pharma America, INC. | $25.34 | 2025 | Myfembree |
| Impel Pharmaceuticals LLC | $24.14 | 2025 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $24.08 | 2025 | Acthar |
| Biohaven Pharmaceuticals, INC. | $21.05 | 2021 | |
| Emd Serono, INC. | $20.69 | 2025 | |
| Daiichi Sankyo INC. | $18.36 | 2019 | |
| Novocure INC. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.